Arlene Sharpe
| Arlene Sharpe | |
|---|---|
| Born | 1953 |
| Nationality | American |
| Alma mater | Harvard College, Harvard Medical School |
| Known for | immune checkpoint blockade |
| Scientific career | |
| Fields | Immunology |
| Institutions | Harvard Medical School |
Arlene Sharpe (born in 1953) is an American immunologist and George Fabyan Professor of Comparative Pathology at Harvard Medical School. In 2017, she received the Warren Alpert Foundation Prize with Gordon Freeman, Lieping Chen, James P. Allison and Tasuku Honjo for their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.[1][2] She served as the hundredth president of the American Association of Immunologists from 2016 to 2017 and served as an AAI Council member from 2013 to 2016.[3] She is the Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital.
She graduated from Harvard College and Harvard Medical School.[4]
Awards and honours
- 1971: Westinghouse Science Talent Search, Captain of Science Award
- 1993: Beckman Young Investigators Award[5]
- 2006: Fellow, American Association for Advancement of Science
- 2014: William B. Coley Award for Distinguished Research in Tumor Immunology
- 2015: Laguna Biotech CEO Forum Award Winner Hall of Fame
- 2017: Warren Alpert Foundation Prize[3]
- 2018: member, National Academy of Sciences
References
- ↑ "2017 Recipient, Arlene Sharpe, Harvard Medical School". www.warrenalpert.org. Retrieved 8 October 2017.
- ↑ "Warren Alpert Foundation Prize Recipients 2017". www.warrenalpert.org. Retrieved 8 October 2017.
- 1 2 "Arlene H. Sharpe, M.D., Ph.D." www.aai.org. Retrieved 8 October 2017.
- ↑ "Arlene Sharpe". Harvard University. Retrieved 2 August 2018.
- ↑ "Arlene H. Sharpe". Arnold and Mabel Beckman Foundation. Retrieved 1 August 2018.
External links